Study to investigate the safety, tolerability and pharmacokinetics of single doses of AZD8566.
Study identifier:D1320C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Randomised, Double Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Oral Doses of AZD8566 in Healthy Volunteers
Medical condition
Healthy Volunteer
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD8566, Placebo
Sex
All
Actual Enrollment
108
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 Aug 2008
Primary Completion Date: 01 Feb 2009
Study Completion Date: 01 Feb 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD8566 solution. Specific dose will be selected by the safety review committee |
| Placebo Comparator: 2 | Drug: Placebo Single 10ml oral solution. |
Contacts
Investigators
Principal Investigator
William Fahy
Clinical Pharmacology Unit, Queen’s Medical Centre, Nottingham, NG7 2UH
